Publications

CalRx Biosimilar Insulin: California’s Initiative to Enter the Insulin Market – Robin Feldman

Insulin: California’s Initiative to Enter the Insulin Market – Robin Feldman

Trade Secrets in Biologic Medicine: The Boundary with Patents – Robin Feldman

The Price Tag of ‘Pay-for-Delay’ – Robin Feldman

Designing Disruption in Pharmaceuticals – Robin Feldman

Captive Generics: The Wolf in Sheep’s Clothing – Robin Feldman

The Devil in the Tiers – Robin Feldman

Leading With the Trailing Edge: Facilitating Patient Choice for Insulin Products – Robin Feldman

Understanding “Evergreening”: Making Minor Modifications Of Existing Medications To Extend Protections – Robin Feldman

Regulatory Property: The New IP – Robin Feldman

The CRISPR Revolution: What Editing Human DNA Reveals About the Patent System’s DNA – Robin Feldman

Reflections from an Outlier: An American Reaction to the EU Rules on Evidence – Richard Marcus